The Drug Discovery World Podcast
DDW Highlights: 23 December 2024
Dec 23, 2024
Recent funding initiatives are making waves in drug discovery, with $300 million secured by an AI-driven firm and Ottimo Pharma's impressive financing. Collaborations, including Tessera Therapeutics and the Gates Foundation, aim to tackle fibrosis and sickle cell disease. Genetic medicine is advancing with breakthroughs for sickle cell treatment and a new bifunctional antibody in cancer therapy. The role of AI in research continues to expand, enhancing capabilities and igniting innovation across the industry.
12:16
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- A collaborative initiative is developing treatments for fibrotic diseases, addressing a neglected area in therapeutic research with only two existing FDA-approved drugs.
- Cradle's successful funding for its AI platform aims to innovate protein engineering, accelerating therapeutic development through enhanced discovery and efficiency in the R&D sector.
Deep dives
Advancements in Fibrosis Treatment
A new initiative aims to establish a company focused on developing innovative treatments for fibrosis, a condition that has long been overlooked in therapeutic research. The collaboration between Venture Studios, Deep Science Ventures, and General Inception seeks to address significant bottlenecks in fibrosis therapeutics, as only two drugs have been FDA-approved for this condition. This new venture will target a range of fibrotic diseases, including pulmonary fibrosis and systemic sclerosis, thereby maximizing the impact of their therapeutic efforts. By prioritizing medical need over technology, the project is poised to make substantial advancements in this neglected area of healthcare.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
